Amgen Tezspire hits 64.8%-68.9% histologic remission in EoE trial vs 3.5% placebo

Amgen reported that Tezspire met primary endpoints in the CROSSING trial for eosinophilic esophagitis. At week 24, 64.8% of patients on 210 mg and 68.9% on 420 mg achieved histologic remission, compared to 3.5% on placebo. Symptom improvement was also observed.